🗞 Verpasste Chance?: Titelgeschichte in der Sonntagsausgabe der Frankfurter Allgemeine Zeitung befasst sich mit der Ablehnung des 🧠⚕️ Alzheimer-Medikaments #Lecanemab durch die Europäische Arzneimittel-Agentur EMA und aktuellen Entwicklungen in der Diagnose und Biomarkerforschung - mit Stimmen aus dem #DZNE. 📰 (Paywall) https://lnkd.in/ec6wSzmn
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
Forschungsdienstleistungen
Bonn, NRW 13.655 Follower:innen
Brain.Research.Life
Info
Das DZNE ist ein biomedizinisches Forschungsinstitut, das sich neurodegenerativen Erkrankungen wie Alzheimer, Parkinson und ALS widmet. Ziel des DZNE ist es, neuartige Strategien der Vorsorge, Diagnose, Behandlung, Pflege und Versorgung zu entwickeln und in die Praxis zu überführen. Das DZNE hat bundesweit 10 Standorte, es kooperiert mit Universitäten, Universitätskliniken und anderen Institutionen im In- und Ausland. Das DZNE wird staatlich gefördert und ist Mitglied der Helmholtz-Gemeinschaft sowie der Deutschen Zentren der Gesundheitsforschung. Folgen Sie uns auf Facebook: www.facebook.com/dzne.de Folgen Sie uns auf Instagram: www.instagram.com/dzne_de Impressum: www.dzne.de/ipressum Datenschutz: www.dzne.de/datenschutz
- Website
-
https://www.dzne.de
Externer Link zu Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
- Branche
- Forschungsdienstleistungen
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Bonn, NRW
- Art
- Nonprofit
- Gegründet
- 2009
- Spezialgebiete
- Neurodegeneration, Neuroscience, Dementia, Translation, Amyotrophic lateral sclerosis, Alzheimer's, Parkinson's, Huntington's, Ataxia und Lewy-Body-Disease
Orte
Beschäftigte von Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
Updates
-
⚕ 🧠 #DZNE-Forscher Gabor Petzold kritisiert, dass sich die Europäische Arzneimittel-Agentur (EMA) gegen eine Zulassung des neuen #Alzheimer-Medikamentes #Lecanemab ausgesprochen hat: 📰 via Helmholtz-Gemeinschaft: https://lnkd.in/e-bazRaP
-
❄ Winter School on Protein Aggregation: 📅 Register by 29 August!
Only ONE DAY left! 🚨 🗻 Join the #FENS-Hertie #WinterSchool on Proteinopathies in Neurodegenerative Disorders! Don't miss this amazing week of scientific exchange and #networking opportunities! Register by 29 August: https://loom.ly/VRC33UE Gemeinnützige Hertie-Stiftung
-
-
#DZNE scientist Monique M.B. Breteler on the health impact of #PFAS, the ubiquitous "forever chemicals" 🧪
🩹 Health consequences of PFAS? Industry and politics must take the issue seriously As part of a study researchers at the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) have gained insights into the spread of PFAS in the blood and the associated health consequences. Study leader Monique M.B. Breteler explains in an interview that the results of her research are unexpected, which is why industry and politicians in particular need to take the issue seriously. 🚩 Find the whole interview about the seriousness of PFAS on #InsideIndustry 👉 https://lnkd.in/dBQTSSxv #Medicaltechnology #Medtech #Safety #health
-
-
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) hat dies direkt geteilt
We're excited to announce that our summer school keynote speakers will be with us very soon. Their lectures promise to deliver invaluable insights and cutting-edge perspectives that you won’t want to miss. We strongly encourage everyone to attend and take advantage of this unique opportunity to learn directly from leading experts in the field. Whether you're eager to deepen your understanding or simply curious about the topics, we warmly welcome you to join us for these impactful sessions. (https://lnkd.in/g3bQbfGZ) P.S. Few places are still available for Ph.D Students and Juonior PostDocs #DZNE #HelmholtzHealth #SummerSchool
-
-
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) hat dies direkt geteilt
🧠 Some media coverage (Spanish & English) on the recent Cell Press paper about the neuromuscular disease SMA by #DZNE scientist Natalia Rodríguez Muela and colleagues: ◽ #Infosalus (Europa Press): https://lnkd.in/eyD_jNkz ◽ Drug Target Review: https://lnkd.in/eWTicq2c ◽ SMA News Today HCP: https://lnkd.in/eGqRhFws ◽ Technology Networks: https://lnkd.in/eWgwmdgJ ◽ Genetic Engineering & Biotechnology News: https://lnkd.in/epip3wBd ✴️ The paper in Cell Reports Medine: https://lnkd.in/e_3RZu2Y
El 'preludio' de la enfermedad neuromuscular puede ofrecer oportunidades para un mejor tratamiento
infosalus.com
-
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) hat dies direkt geteilt
🧠 Our recent Nature Portfolio paper on blood biomarkers for #FTD and other neurodegenerative diseases (a collaboration with Universitätsklinikum Bonn, Institut de Recerca Sant Pau and others) was picked up by media in Europe and beyond - here are some examples: ◽ Deutsches Ärzteblatt: https://lnkd.in/eyTZnNHz ◽ Alzforum: https://lnkd.in/eV-35JC9 ◽ SciTechDaily: https://lnkd.in/eYDCCPF2 ◽ The Tribune: https://lnkd.in/eX5TAT5b ◽ Diario EL PAÍS: https://lnkd.in/eHWuc7HB ◽ El Periódico: https://lnkd.in/eNVbnN4n ◽ Pourquoi Docteur Media: https://lnkd.in/ehzmmR83 ◽ ANSA: https://lnkd.in/enS3wgMK ◽️Gulf Today: https://lnkd.in/dx4HRzhw 📰 The paper in #NatureMedicine: https://lnkd.in/eRNGzZZV
Forschende identifizieren Blutbiomarker für frontotemporale Demenz
aerzteblatt.de
-
💊 🔬 📺 In this video #DZNE scientist Fava Eugenio talks about research into novel drugs
Expert in High-Content Imaging & Pharmaceutical Research | 20-Year Track Record of Leading Drug Discovery & Tech Innovation Projects | Founder & Senior Advisor
𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗶𝘁𝗵 𝗘𝘂𝗴𝗲𝗻𝗶𝗼 𝗙𝗮𝘃𝗮 https://lnkd.in/dBWgVqRT Introduction to Video Series with Eugenio Fava on YouTube Join renowned scientist Eugenio Fava as he delves into the intricacies of the drug discovery process. With his extensive expertise in neuroscience and pharmaceutical research, Eugenio provides a deep dive into strategic approaches for understanding diseases, identifying key targets, and developing effective drugs using advanced technologies. Key Highlights: • 𝗔𝗰𝗮𝗱𝗲𝗺𝗶𝗰 𝘃𝘀. 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗥𝗼𝗹𝗲𝘀: Compare the unique challenges and contributions of academic institutions and pharmaceutical companies in drug discovery. • 𝗖𝘂𝘁𝘁𝗶𝗻𝗴-𝗘𝗱𝗴𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀: Learn about the critical role of artificial intelligence, innovative 3D cell models, stem cell technologies, and single-cell techniques in revolutionizing drug screening and development. • 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: Explore the pressing issues researchers face today and the future trends shaping the field. 𝗪𝗵𝘆 𝗪𝗮𝘁𝗰𝗵? • Gain practical insights from a leading expert. • Understand the latest trends and technologies in drug discovery. • Discover the distinct approaches and challenges within academia and industry. Tune in for an enlightening conversation with @𝗘𝘂𝗴𝗲𝗻𝗶𝗼𝗙𝗮𝘃𝗮 and unlock valuable knowledge that could transform your understanding and approach to pharmaceutical research. 🔗 If you'd like to delve deeper into this topic with Eugenio, you can listen to the full interview here: https://lnkd.in/djxjeCrh 🔜 Stay Tuned: #CELLIMATALKS will continue for more on #drugdiscovery, #highcontentimaging, and #bigdata applications in #pharmaceuticalresearch. CELLIMA Scientific Service GmbH #lifesciences #CellPainting #Healthcare
Insights into Drug Discovery with Eugenio Fava ›» «‹ #podcast #science #innovation
https://www.youtube.com/
-
📅 On October 8, experts from research and medicine will meet in #Berlin for the 1st #HelmholtzHealthSummit of the Helmholtz-Gemeinschaft. Participants include #DZNE scientist and #Parkinson's expert Thomas Gasser #HelmholtzHealthHero 👉 Register via: https://lnkd.in/dXDt_URe
-
-
📅 On October 8, experts from research and medicine will meet in #Berlin for the 1st #HelmholtzHealthSummit of the Helmholtz-Gemeinschaft. Participants include #DZNE scientist Joachim Schultze #HelmholtzHealthHero #ArtificialIntelligence #SwarmLearning 👉 Register via: https://lnkd.in/dXDt_URe
-